InvestorsHub Logo
Post# of 174979
Next 10
Followers 914
Posts 4481
Boards Moderated 0
Alias Born 03/26/2018

Re: None

Sunday, 10/21/2018 11:16:40 PM

Sunday, October 21, 2018 11:16:40 PM

Post# of 174979
RadioGel does what no treatment can-->

First Successful Treatment of Canine Sarcoma using IsoPet® to be Presented at Veterinary Cancer Society Conference

Richland, WA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC PINK: RDGL) first therapy to canine treat soft tissue sarcoma is successful IsoPet®, was used to treat a hind-leg soft-tissue sarcoma in a Sheltie at the University of Missouri Veterinary Health Center in Columbia, Missouri.

Veterinary oncologist, Dr. Charles Maitz, reported that the treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery. Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Kentucky, October 17 – 20, 2018.

After therapy the pet owner commented that the dog had more energy than she can remember for a long time. “The owner is delighted!” said Dr. Maitz.

Study investigators were also pleased that IsoPet® met all RadioGel™ design performance criteria. Post-treatment imaging and dosimetry provided confirmatory data addressing the principal questions previously raised by an FDA review panel, including:

Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues. Very high therapeutic ratios (radiation dose to the tumor relative to normal organs)

Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues.

The University of Missouri is now advertising availability of IsoPet® treatment for dogs and other species, including treatment of equine (horse) sarcoids.

Mike Korenko, Vivos Inc CEO stated “The successful treatment of the cat and dog subjects thus far increases the likelihood of IsoPet® becoming a practical solution in the treatment of animal cancer. Additionally, the data obtained at the University of Missouri will support the pre-clinical investigations required by the FDA to provide evidence that RadioGel™ can be safe and effective for treating various human cancers.”



$RDGL

"Sir, you are entitled to your own opinions, but you are not entitled to your own facts!"



T.D.F. Captain (Ticker Defense Force)

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News